We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Hologic (HOLX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.05 per share, reflecting a decline of 0.9% compared to the same period last year. Revenues are forecasted to be $1.01 billion, representing a year-over-year decrease of 0.4%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Hologic metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenues- GYN surgical' will likely reach $179.82 million. The estimate points to a change of +7.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular diagnostics' should arrive at $316.12 million. The estimate points to a change of +1.8% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Diagnostics- Blood screening' will reach $5.65 million. The estimate indicates a year-over-year change of -28.5%.
Analysts expect 'Revenues- Breast health- Breast imaging' to come in at $277.39 million. The estimate indicates a change of -10.3% from the prior-year quarter.
Analysts predict that the 'Revenues- Total Diagnostics' will reach $437.46 million. The estimate suggests a change of -0.8% year over year.
The consensus among analysts is that 'Revenues- Skeletal health' will reach $25.34 million. The estimate points to a change of +33.4% from the year-ago quarter.
Analysts forecast 'Revenues- Diagnostics- Cytology and perinatal' to reach $117.36 million. The estimate indicates a year-over-year change of -4%.
According to the collective judgment of analysts, 'Revenues- Total Breast health' should come in at $363.15 million. The estimate points to a change of -5.7% from the year-ago quarter.
The consensus estimate for 'Revenues- Breast health- Interventional breast solutions' stands at $85.76 million. The estimate indicates a year-over-year change of +13.1%.
The average prediction of analysts places 'Revenues- Service and other' at $202.73 million. The estimate indicates a year-over-year change of +1.3%.
Analysts' assessment points toward 'Revenues- Product' reaching $801.50 million. The estimate points to a change of -1.2% from the year-ago quarter.
Hologic shares have witnessed a change of +1.5% in the past month, in contrast to the Zacks S&P 500 composite's +4.6% move. With a Zacks Rank #4 (Sell), HOLX is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Hologic (HOLX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.05 per share, reflecting a decline of 0.9% compared to the same period last year. Revenues are forecasted to be $1.01 billion, representing a year-over-year decrease of 0.4%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Hologic metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenues- GYN surgical' will likely reach $179.82 million. The estimate points to a change of +7.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular diagnostics' should arrive at $316.12 million. The estimate points to a change of +1.8% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Diagnostics- Blood screening' will reach $5.65 million. The estimate indicates a year-over-year change of -28.5%.
Analysts expect 'Revenues- Breast health- Breast imaging' to come in at $277.39 million. The estimate indicates a change of -10.3% from the prior-year quarter.
Analysts predict that the 'Revenues- Total Diagnostics' will reach $437.46 million. The estimate suggests a change of -0.8% year over year.
The consensus among analysts is that 'Revenues- Skeletal health' will reach $25.34 million. The estimate points to a change of +33.4% from the year-ago quarter.
Analysts forecast 'Revenues- Diagnostics- Cytology and perinatal' to reach $117.36 million. The estimate indicates a year-over-year change of -4%.
According to the collective judgment of analysts, 'Revenues- Total Breast health' should come in at $363.15 million. The estimate points to a change of -5.7% from the year-ago quarter.
The consensus estimate for 'Revenues- Breast health- Interventional breast solutions' stands at $85.76 million. The estimate indicates a year-over-year change of +13.1%.
The average prediction of analysts places 'Revenues- Service and other' at $202.73 million. The estimate indicates a year-over-year change of +1.3%.
Analysts' assessment points toward 'Revenues- Product' reaching $801.50 million. The estimate points to a change of -1.2% from the year-ago quarter.
View all Key Company Metrics for Hologic here>>>Hologic shares have witnessed a change of +1.5% in the past month, in contrast to the Zacks S&P 500 composite's +4.6% move. With a Zacks Rank #4 (Sell), HOLX is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .